Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society
Clin Investig Arterioscler. 2022 Nov-Dec;34(6):303-310.
doi: 10.1016/j.arteri.2022.03.007.
Epub 2022 May 30.
[Article in
English,
Spanish]
Affiliations
- 1 Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, España; Universidad de Zaragoza, Zaragoza, España.
- 2 Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, España.
- 3 Sección de Endocrinología y Nutrición, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, España; Instituto Universitario de Investigaciones Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España.
- 4 Unidad de Medicina Vascular y Metabolismo, Hospital Universitari Sant Joan, Reus, Instituto de Investigación Sanitaria Pere Virgili (IISPV), CIBERDEM, Universidad Rovira i Virgili, Tarragona, España.
- 5 Unidad de Lípidos, Servicio de Medicina Interna, Hospital Virgen de la Victoria, Departamento de Medicina y Dermatología, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, España.
- 6 Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, España; Universidad de Zaragoza, Zaragoza, España. Electronic address: civeira@unizar.es.
Abstract
Introduction:
Clinical studies show that patients with high cardiovascular risk are still far from reaching the therapeutic objectives, especially of the levels of LDL cholesterol. If the management of these patients in specialized units differs from other scenarios is known.
Patients and methods:
61 certified Lipid Units were selected in the Registry of Dyslipemias of the Spanish Arteriosclerosis Society for the collection of study data. The study included 3958 subjects >18 years of age who met the criteria for hypercholesterolemia (LDL cholesterol ≥160 mg/dL or non-HDL cholesterol ≥190 mg/dL) without familial hypercholesterolemia. A total 1,665 subjects were studied with a mean follow-up time of 4.2 years.
Results and conclusions:
A total of 42 subjects had a cardiovascular event since their inclusion in the Registry, which represents 0.6%. There were no differences in the treatment used at follow-up, but 50% of the patients did not reach the therapeutic goals at the visit end of follow-up. An increase in the potency of the lipid-lowering treatment was observed, including PCSK9 inhibitors use in 16.7% of subjects with recurrences.
Keywords:
Estatinas; Prevención primaria; Prevención secundaria; Primary prevention; Secondary prevention; Statins.
Copyright © 2022 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Anticholesteremic Agents* / therapeutic use
-
Arteriosclerosis* / drug therapy
-
Cholesterol, LDL
-
Dyslipidemias* / complications
-
Dyslipidemias* / drug therapy
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
-
Proprotein Convertase 9
-
Registries
-
Secondary Prevention
Substances
-
Cholesterol, LDL
-
PCSK9 protein, human
-
Proprotein Convertase 9
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Anticholesteremic Agents